Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
"Soluble E-Selectin in Cancer Patients as a Marker of the Therapeutic Efficacy of CM101, a Tumor-Inhibiting Anti-Neovascularization Agent, Evaluated in Phase I Clinical Trial."
May 26th, 1997
According to the authors' abstract of an article published in Journal of Cancer Research and Clinical Oncology, "A polysaccharide toxin, GBS toxin, is produced by group B Streptococcus (GBS) isolates from neonates who died of 'early-onset disease.' GBS toxin, named CM101 in the clinic, was hypothesized, on the basis of our previous in vivo studies, to induce inflammation in pulmonary neovasculature in neonates by cross-linking of embryonic receptors still expressed after birth and in tumor neovasculature in adults. Immunohistochemical in vitro analysis of human biopsies showed that tumor neovasculature is indeed a binding site for CM101. In vivo studies in mice have demonstrated that...
Source: Cancer Weekly (1997-05-26)
|
|
Advertisement |
|
|
